Skip to content

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung Thi Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer Saba Azad, Dan A. Laheru, Barbara A. Biedrzycki, Ross C. Donehower, Atif Zaheer, George Albert Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, Feriyl Bhaijee, Thomas A. Huebner, Ralph H. Hruban, Laura DeLong Wood, Nathan S. Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis Marie Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis Alberto Diaz

New England Journal of Medicine · 2015 · 9,526 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D. A., Biedrzycki, B. A., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., Chapelle, A. de la, … Diaz, L. A. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509–2520. https://doi.org/10.1056/nejmoa1500596

In text: (Le et al., 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade. METHODS: We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti-programmed death 1 immune checkpoint inhibitor, in 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency. Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with mismatch repair-deficient colorectal cancers, patients with mismatch repair-proficient colorectal cancers, and patients with mismatch repair-deficient cancers that were not colorectal. The coprimary end points were the immune-related objective response rate and the 20-week immune-related progression-free survival rate. RESULTS: The immune-related objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patients) and 78% (7 of 9 patients), respectively, for mismatch repair-deficient colorectal cancers and 0% (0 of 18 patients) and 11% (2 of 18 patients) for mismatch repair-proficient colorectal cancers. The median progression-free survival and overall survival were not reached in the cohort with mismatch repair-deficient colorectal cancer but were 2.2 and 5.0 months, respectively, in the cohort with mismatch repair-proficient colorectal cancer (hazard ratio for disease progression or death, 0.10 [P<0.001], and hazard ratio for death, 0.22 [P=0.05]). Patients with mismatch repair-deficient noncolorectal cancer had responses similar to those of patients with mismatch repair-deficient colorectal cancer (immune-related objective response rate, 71% [5 of 7 patients]; immune-related progression-free survival rate, 67% [4 of 6 patients]). Whole-exome sequencing revealed a mean of 1782 somatic mutations per tumor in mismatch repair-deficient tumors, as compared with 73 in mismatch repair-proficient tumors (P=0.007), and high somatic mutation loads were associated with prolonged progression-free survival (P=0.02). CONCLUSIONS: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; ClinicalTrials.gov number, NCT01876511.).

  1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
  3. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
  4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016

Metadata from OpenAlex (CC0). Citations are generated from the published record.